

Supplement for: Association of PET4 Response With Outcomes of BV-CHP vs CHOP in the ECHELON-2 Trial in CD30+ Peripheral T-cell Lymphoma

Supplementary Table 1. Disease characteristics¹





Characteristic	BV-CHP n = 226	CHOP n = 226
Diagnosis, n (%) [†]		
sALCL	162 (72)	154 (68)
ALK positive	49 (22)	49 (22)
ALK negative	113 (50)	105 (46)
PTCL-NOS	29 (13)	43 (19)
AITL	30 (13)	24 (11)
ATLL	4 (2)	3 (1)
EATL	1 (0)	2 (1)
Disease stage at diagnosis, n (%) [‡]		
Stage I	12 (5)	9 (4)
Stage II	30 (13)	37 (16)
Stage III	57 (25)	67 (30)
Stage IV	127 (56)	113 (50)
Baseline IPI scored, n (%) [§]		
0	8 (4)	16 (7)
1	45 (20)	32 (14)
2	74 (33)	78 (35)
3	66 (29)	66 (29)
4	29 (13)	25 (11)
5	4 (2)	9 (4)

Data shown are for the intent-to-treat population. Percentages may not total 100 because of rounding. *Values for ECOG performance status range from 0 to 5, with higher scores indicating greater disability. [†]Diagnosis per local assessment. [‡]The Ann Arbor staging system ranges from I to IV, with higher stages indicating more widespread disease. [§]The IPI score is determined based on a patient's disease characteristics and represents increasing degrees of risk.

AITL, angioimmunoblastic T-cell lymphoma; ALK, anaplastic lymphoma kinase; ATLL, adult T-cell leukemia/lymphoma; BV-CHP, brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; EATL, enteropathy-associated T-cell lymphoma; ECOG, Eastern Cooperative Oncology Group; IPI, international prognostic index; PTCL-NOS, peripheral T-cell lymphoma-not otherwise specified; sALCL, systemic anaplastic large cell lymphoma.


1. Horwitz S, O'Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. *Lancet*. 2019;393(10168):229-240.

Supplementary Figure 1. PFS in the BV-CHP (A) and CHOP (B) arms and OS in the BV-CHP (C) and CHOP (D) arms by cycle 4 PET Deauville score



BV-CHP, brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone; CI, confidence interval; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; DS, Deauville score; HR, hazard ratio; OS, overall survival; PET, positron emission tomography; PFS, progression-free survival.


Supplementary Figure 2. PFS in the BV-CHP (A) and CHOP (B) arms and OS in the BV-CHP (C) and CHOP (D) arms by cycle 4 PET Deauville score (sALCL subgroup)



BV-CHP, brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone; CI, confidence interval; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; DS, Deauville score; HR, hazard ratio; OS, overall survival; PET, positron emission tomography; PFS, progression-free survival; sALCL, systemic anaplastic large cell lymphoma.


Supplementary Figure 3. Sensitivity analysis of PFS in the BV-CHP (A) and CHOP (B) arms by cycle 4 PET status

A.



No. at risk (events)	
PET4-negative	175(0) 158(14) 136(34) 126(43) 113(49) 96(52) 80(56) 62(59) 38(63) 28(64) 20(65) 10(67) 4(67) 2(67) 0(68) 0(68)
PET4-positive	19(0) 12(6) 8(9) 7(10) 7(10) 7(10) 4(10) 4(10) 4(10) 2(11) 1(11) 0(11) 0(11) 0(11) 0(11) 0(11)

B.



No. at risk (events)	
PET4-negative	147(0) 134(11) 110(35) 102(42) 90(51) 83(54) 72(56) 63(58) 53(58) 37(58) 23(60) 6(63) 0(64) 0(64) 0(64) 0(64)
PET4-positive	38(0) 19(19) 12(26) 9(28) 6(28) 5(29) 4(29) 4(29) 1(29) 1(29) 1(29) 1(29) 0(29) 0(29) 0(29) 0(29)

Sensitivity analysis was conducted by cycle 4 PET status, in which receipt of new anticancer therapy was not considered an event nor a reason for censoring and in which patients who died or progressed after more than one consecutively missed radiographic tumor assessment were considered to have had an event on the date of death or progression.

BV-CHP, brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone; CI, confidence interval; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; HR, hazard ratio; PET, positron emission tomography; PFS, progression-free survival.